Eunhyang J. Park

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.

Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.

Journal: Gynecologic oncology

Published: August 26, 2025

Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma.

Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 20, 2024

Modifying surgical extents in patients with preoperatively presumed early-stage endometrial cancer based on ProMisE classification: a retrospective, single-center study.

Modifying surgical extents in patients with preoperatively presumed early-stage endometrial cancer based on ProMisE classification: a retrospective, single-center study.

Journal: Journal of gynecologic oncology

Published: December 03, 2024

Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.

Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 09, 2024

Categorizing high-grade serous ovarian carcinoma into clinically relevant subgroups using deep learning-based histomic clusters.

Categorizing high-grade serous ovarian carcinoma into clinically relevant subgroups using deep learning-based histomic clusters.

Journal: Journal of pathology and translational medicine

Published: September 03, 2024

Multimodal AI model for preoperative prediction of axillary lymph node metastasis in breast cancer using whole slide images.

Multimodal AI model for preoperative prediction of axillary lymph node metastasis in breast cancer using whole slide images.

Journal: NPJ precision oncology

Published: July 22, 2024

Optimal Positioning of Load-Distributing Band CPR Device by Body Mass Index.

Optimal Positioning of Load-Distributing Band CPR Device by Body Mass Index.

Journal: Journal of clinical medicine

Published: July 03, 2024

Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.

Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.

Journal: Gynecologic oncology

Published: May 02, 2024

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer.

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer.

Journal: Frontiers in oncology

Published: December 07, 2023

Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.

Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.

Journal: The American journal of surgical pathology

Published: November 20, 2023

Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".

Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".

Journal: International journal of cancer

Published: October 11, 2023

Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.

Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.

Journal: Gynecologic oncology

Published: September 06, 2023

Showing 1-12 of 54

Last Updated: 09/26/2026